Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nuvalent Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NUVL
Nasdaq
8731
https://www.nuvalent.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nuvalent Inc
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
- Apr 8th, 2024 8:30 pm
Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
- Apr 5th, 2024 11:00 pm
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
- Apr 5th, 2024 10:30 pm
Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)
- Mar 29th, 2024 11:01 pm
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)
- Mar 25th, 2024 11:01 pm
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
- Mar 22nd, 2024 1:35 pm
Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)
- Mar 19th, 2024 11:01 pm
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
- Mar 5th, 2024 9:52 pm
Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ...
- Feb 29th, 2024 9:32 am
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 11:30 am
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
- Feb 27th, 2024 11:15 am
13 Best Short Squeeze Stocks To Buy Now
- Feb 22nd, 2024 9:00 am
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
- Feb 12th, 2024 11:30 am
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 1st, 2024 11:30 am
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
- Jan 8th, 2024 11:30 am
Nuvalent, Inc. (NASDAQ:NUVL) Shares Could Be 35% Below Their Intrinsic Value Estimate
- Jan 1st, 2024 12:50 pm
Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL)
- Dec 22nd, 2023 8:01 pm
Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL)
- Dec 21st, 2023 6:01 pm
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 21st, 2023 11:30 am
Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress
- Nov 15th, 2023 12:15 am
Scroll